Lantern Pharma Completes Early Enrollment in Japan for Lung Cancer Trial Targeting Never-Smokers

Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced the successful completion of targeted enrollment for its Phase 2 HARMONIC™ clinical trial in Japan. The company enrolled 10 patients ahead of schedule across five clinical sites in Japan, including the National Cancer Center Japan.

The HARMONIC™ trial is evaluating LP-300 in combination with carboplatin and pemetrexed in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The successful Japanese enrollment validates Lantern's strategic decision to expand the trial internationally to regions with significantly higher rates of never-smoker NSCLC patients such as Japan and Taiwan.